News - secukinumab, Novartis

Filter

Current filters:

secukinumabNovartis

Popular Filters

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Novartis reports further progress with its psoriasis candidate secukinumab

Novartis reports further progress with its psoriasis candidate secukinumab

08-10-2013

Novartis recently announced results from the head-to-head Phase III FIXTURE study showing secukinumab…

DermatologicalsNovartisPharmaceuticalResearchsecukinumab

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study

08-07-2013

Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Novartis' secukinumab significantly effective in hard-to-treat plaque psoriasis

27-09-2012

September 27, 2012 Swiss drug major Novartis (NOVN: VX) this morning announced new Phase II data…

AIN457DermatologicalsNovartisPharmaceuticalResearchsecukinumab

Back to top